RxDoctor Payments Data

Gretchen Bishop

Family · Chicora, PANPI 1053514539

Payments from drug & device makers

$1,126in general payments, 2019–2025

Across 54 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$400
  • Abbott$177
  • GSK$158
  • Lilly USA, LLC$98
  • Grifols USA, LLC$76
  • AstraZeneca$67
  • plus $151 from 7 others

What the payments were for

  • Food & beverage$1,126100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,126 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$30,878
Medicare patients
105
Services billed
321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$148,713
JardianceEmpagliflozin84$94,245
EliquisApixaban76$60,899
XareltoRivaroxaban38$44,492
TrulicityDulaglutide29$43,560
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$36,116
JanuviaSitagliptin Phosphate20$31,657
Spiriva RespimatTiotropium Bromide28$22,886
MyrbetriqMirabegron37$20,684
Breo ElliptaFluticasone/Vilanterol28$11,153
RybelsusSemaglutide12$10,992
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,042
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$5,593
Albuterol Sulfate HfaAlbuterol Sulfate127$4,644
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$400$159,705128 claims
PfizerEliquis$29$60,89976 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$158$55,84594 claims
Johnson & JohnsonXarelto$14$44,49238 claims
Lilly USA, LLCTrulicity$98$43,56029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Chicora

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →